Live Breaking News & Updates on Saag Session

Stay updated with breaking news from Saag session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol

- Data presented at European Atherosclerosis Society 92nd Congress. ....

Daniel Gaudet , Coll Cardiol , Gugliucciaj Clin , Robert Rosenson , Christiem Ballantyne , Baylor College Of Medicine , Arrowhead Pharmaceuticals Inc , Exchange Commission , European Atherosclerosis Society , Arrowhead Pharmaceuticals , European Medicines Agency , Drug Administration , New England Journal , Baylor College , Principal Investigator , Atherosclerosis Society , New Therapeutics , Saag Session , Late Breaker Session , New Therapeutic Agents , Orphan Drug Designation , Fast Track Designation , European Medicines , Harbor Statement , Private Securities Litigation Reform Act , Annual Report ,